Summary
Edwards Lifesciences Corporation (EW) reported strong top-line growth in its second quarter and first six months of 2025, with net sales increasing by 11.9% and 9.1% respectively compared to the prior year. This growth was primarily driven by robust performance in Transcatheter Aortic Valve Replacement (TAVR) and a significant surge in Transcatheter Mitral and Tricuspid Therapies (TMTT) sales, up 61.9% and 60.1% for the respective periods. The company also saw continued growth in its Surgical Structural Heart segment. While revenue growth was positive, gross profit margin experienced a slight decline due to higher manufacturing expenses for new therapies and foreign currency impacts. The company also recorded a notable loss on impairment of $47.1 million related to an unexercised acquisition option. The balance sheet shows an increase in cash and cash equivalents and a decrease in accounts payable. Investors should monitor the company's ongoing litigation and tax matters, particularly the significant IRS transfer pricing dispute, which continues to present a potential financial risk.
Financial Highlights
50 data points| Revenue | $1.53B |
| Cost of Revenue | $344.40M |
| Gross Profit | $1.19B |
| R&D Expenses | $276.20M |
| SG&A Expenses | $502.00M |
| Operating Income | $411.20M |
| Net Income | $331.50M |
| EPS (Basic) | $0.57 |
| EPS (Diluted) | $0.56 |
| Shares Outstanding (Basic) | 587.00M |
| Shares Outstanding (Diluted) | 587.90M |
Key Highlights
- 1Net sales increased by 11.9% to $1.53 billion for the three months ended June 30, 2025, and by 9.1% to $2.94 billion for the six months ended June 30, 2025, compared to the prior year.
- 2Transcatheter Mitral and Tricuspid Therapies (TMTT) sales saw substantial growth, increasing by 61.9% and 60.1% for the three-month and six-month periods respectively.
- 3Gross profit margin decreased slightly due to higher manufacturing expenses and foreign currency fluctuations.
- 4The company recorded a $47.1 million loss on impairment related to a decision not to exercise an option to acquire a medical device company.
- 5Cash and cash equivalents increased to $3.27 billion as of June 30, 2025, up from $3.05 billion at December 31, 2024.
- 6The company is actively managing a significant IRS transfer pricing dispute, with potential tax liabilities and ongoing legal proceedings.
- 7Edwards Lifesciences continues to execute its share repurchase program, with $1.1 billion remaining authorization as of June 30, 2025.